The obesity-drug market is now moving to a much more complicated phase. The first major battle was largely fought between two obesity injectable GLP-1 drugs, Eli Lilly's (LLY) Zepbound and Novo's (NVO) Wegovy. But this next round is increasingly becoming about oral treatments, higher-dose formulations, and next-generation drugs that could extend the market well beyond today's blockbuster therapies.
For investors, it is no longer simply about which company sells the most weight-loss injections now. It is about which business has the stronger chance of winning the next phase and benefits investors over the long haul.
